Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABSI with free AI briefings, catalyst countdowns, and dilution alerts.

ABSI · Absci Corporation

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$218.3M Cash on Hand
23mo Cash Runway
29.7% Short Interest
$8.05 Analyst Target (7)
Follow ABSI by email Get an email when ABSI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABSI, unsubscribe in one click. Privacy

📣 What ABSI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ABS-201 SC Multiple Doses Androgenetic Alopecia (AGA) Phase 1/2 · NCT07317544 Recruiting
SAD IV Dose 1 - 150mg ABS201 IV Single Dose Androgenetic Alopecia (AGA) Phase 1/2 · NCT07317544 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABSI holds $218.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $28.5M/quarter from operations, an estimated runway of 23 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABSI files for a raise →

👥 Who Owns ABSI

Insiders 6% Institutions (300 holders) 91.2% Public and other holders 2.8%
HolderTypeShares% of sharesAs of
FMR, LLC Institution (13F) 22,382,002 13.04% 2025-12-31
BlackRock, Inc. Institution (13G, 5%+) 13,396,310 7.81% 2026-09-30
ARK Investment Management LLC Institution (13G, 5%+) 11,928,917 6.95% 2026-09-30
Sean McClain
Chief Executive Officer, Director · +3.21M options
Insider 8,552,402 4.98% 2026-10-29
Redmile Group, LLC Institution (13F) 8,253,316 4.81% 2025-12-31
Vanguard Group Inc Institution (13F) 7,910,205 4.61% 2025-12-31
State Street Corporation Institution (13F) 5,990,877 3.49% 2025-12-31
Advanced Micro Devices Inc Institution (13F) 5,714,285 3.33% 2025-12-31
Geode Capital Management, LLC Institution (13F) 3,239,623 1.89% 2025-12-31
Ameriprise Financial, Inc. Institution (13F) 3,196,577 1.86% 2025-12-31
UBS Group AG Institution (13F) 2,699,505 1.57% 2025-12-31
Zachariah Jonasson
CFO / CBO · +1.07M options
Insider 484,918 0.28% 2026-10-12

Share count 171,614,010 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-31
filed 2026-09-01
Jonasson Zachariah
Tax withholding (F) 8,320 $8.71 483,144
2026-08-03
filed 2026-08-07
Somaratne Ransi Mudalinayake
Option award (A) 383,000 – –
2026-03-03
filed 2026-08-07
Somaratne Ransi Mudalinayake
Option award (A) 650,000 – –
2026-06-30
filed 2026-07-06
Szela Mary T
Purchase (P) 12,900 $11.54 21,300
2026-06-24
filed 2026-06-26
McClain Sean
Tax withholding (F) 59,896 $10.08 8,655,555

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ABSI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABSI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.